Novo Nordisk acquires Danish biotech company

With the acquisition of Copenhagen-based biotech company Embark Biotech and its lead candidate, Novo Nordisk once again adds new opportunities to the pharmaceutical company’s obesity pipeline. 
The team behind Embark Biotech
The team behind Embark Biotech

Just a few weeks ago, Novo Nordisk announced the acquisition of Canadian biotech company Inversago Pharma, whose main product is being developed to treat obesity. And the pharmaceutical company has now done it again. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading